Lu Wenge, Lin Jiayuh, Chen Jiandong
Molecular Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA.
Cancer Res. 2002 Mar 1;62(5):1305-10.
Tumors without p53 mutation are often resistant to p53 gene therapy. We examined the mechanism using p53-resistant A549 cells and p53-sensitive H1299 cells. We found that p53 delivered by adenovirus is poorly expressed in A549 (ARF-null) cells but efficiently expressed in H1299 cells (ARF-positive). Strong p53 expression and apoptosis can be achieved in A549 cells using a p53 mutant resistant to degradation by MDM2 or by coexpression of ARF. The results suggest that enhanced MDM2 activity attributable to loss of ARF contributes to p53 resistance. Surprisingly, tumor cell lines with MDM2 gene amplification are still deficient for ARF expression, suggesting that MDM2 amplification does not substitute for ARF inactivation during tumor development.
没有p53突变的肿瘤通常对p53基因治疗有抗性。我们使用对p53有抗性的A549细胞和对p53敏感的H1299细胞来研究其机制。我们发现,腺病毒递送的p53在A549(ARF缺失)细胞中表达不佳,但在H1299细胞(ARF阳性)中高效表达。使用对MDM2介导的降解有抗性的p53突变体或通过共表达ARF,可以在A549细胞中实现强烈的p53表达和细胞凋亡。结果表明,ARF缺失导致的MDM2活性增强促成了p53抗性。令人惊讶的是,具有MDM2基因扩增的肿瘤细胞系仍然缺乏ARF表达,这表明在肿瘤发生过程中MDM2扩增不能替代ARF失活。